$SCPS: Scopus BioPharma Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer.
See the @sitcancer announcement:
scopusbiopharma.com/scopus-b…
$SCPS: “These new data suggest there is compelling potential for significant anti-tumor activity in gliomas utilizing a combination of DUET-102 with PD-1 inhibitors, such as Keytruda (Merck), Opdivo (Bristol-Myers Squibb) and Libtayo (Regeneron).”
- Dr. Kortylewski, Duet
$SCPS: “Our new data demonstrate potent anti-tumor activity in malignant glioma. We are extremely excited about the significant potential of DUET-102 to be a game-changing and much-needed new treatment option for glioma patients.”
- Duet CEO Alan Horsager
$SCPS: Scopus BioPharma Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer on November 4th.
More information on the presentation at @SITCancer:
scopusbiopharma.com/scopus-b…
Scopus BioPharma (Nasdaq: $SCPS) Subsidiary— Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer. For details on this SITC $SCPS presentation, see here:
scopusbiopharma.com/scopus-b…
Scopus BioPharma (Nasdaq: $SCPS) Completes Recapitalization Designed to Enhance Shareholder Value - Learn More About These $SCPS Transactions:
scopusbiopharma.com/scopus-b…
“I am delighted to resume serving on the $SCPS Board. Having founded and nurtured many successful biotech companies, I am extremely excited about the Duet Platform, which encompasses an exceptional and comprehensive portfolio of immuno-oncology assets.” - Dr. Hofstein commented
The $SCPS in-person presentation will be part of Track 4 on Tuesday, October 12, 2021 at 11 AM ET / 8 AM PT at the Luxe Sunset Bel-Air in Los Angeles. The presentation will also be available for viewing on-demand on the LD Micro conference website.